Our trial provides proof of concept that cytokine-armored CAR T-cell treatment is feasible and may enhance antitumor activity without additional toxic effects,” researchers reported.

The characteristics of the patients are described in Table 1 and Table S1 ... One patient had not received previous anti-CD19 CAR T-cell therapy owing to two unsuccessful attempts at the ...

Discover a study that explores the effectiveness of a novel CAR T cell therapy for acute lymphoblastic leukaemia.

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following novel in vivo CD19 CAR-T therapy.

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

Genocury launched the in vivo CD19 CAR-T therapy to reach the clinical stage, demonstrating exceptional safety, efficiency ...

CAR T-cell product showed promising efficacy and safety in a phase I trial of lymphoma patients who had previously failed ...

Unlike conventional CAR-T, which carries a ~50% risk of cytokine ... with increased infection risk- further underscores the therapy's safety profile.